PMID- 33761993
OWN - NLM
STAT- MEDLINE
DCOM- 20210708
LR  - 20210708
IS  - 1757-6512 (Electronic)
IS  - 1757-6512 (Linking)
VI  - 12
IP  - 1
DP  - 2021 Mar 24
TI  - The combination of G-CSF and AMD3100 mobilizes bone marrow-derived stem cells to 
      protect against cisplatin-induced acute kidney injury in mice.
PG  - 209
LID - 10.1186/s13287-021-02268-y [doi]
LID - 209
AB  - BACKGROUND: Several studies have confirmed that mobilizing bone marrow-derived 
      stem cells (BMSCs) ameliorates renal function loss following cisplatin-induced 
      acute kidney injury (AKI). The aim of this study was to explore whether the 
      combination of granulocyte-colony stimulating factor (G-CSF) and plerixafor 
      (AMD3100) exerts beneficial effects on renal function recovery in a model of 
      cisplatin-induced nephrotoxicity. METHODS: C57BL/6J mice received intraperitoneal 
      injections of G-CSF (200 mug/kg/day) for 5 consecutive days. On the day of the 
      last injection, the mice received a single subcutaneous dose of AMD3100 (5 mg/kg) 
      1 h before cisplatin 20 mg/kg injection. Ninety-six hours after cisplatin 
      injection, the mice were euthanized, and blood and tissue samples were collected 
      to assess renal function and tissue damage. Cell mobilization was assessed by 
      flow cytometry (FCM). RESULTS: Mice pretreated with G-CSF/AMD3100 exhibited 
      longer survival and lower serum creatinine and blood urea nitrogen (BUN) levels 
      than mice treated with only G-CSF or saline. Combinatorial G-CSF/AMD3100 
      treatment attenuated tissue injury and cell death, enhanced cell regeneration, 
      and mobilized a higher number of stem cells in the peripheral blood than G-CSF or 
      saline treatment. Furthermore, the mRNA expression of proinflammatory factors was 
      lower, whereas that of anti-inflammatory factors was higher, in the G-CSF/AMD3100 
      group than in the G-CSF or saline group (all P < 0.05). CONCLUSIONS: These 
      results suggest that combinatorial G-CSF/AMD3100 therapy mobilizes BMSCs to 
      accelerate improvements in renal functions and prevent cisplatin-induced renal 
      tubular injury. This combinatorial therapy may represent a new therapeutic option 
      for the treatment of AKI and should be further investigated in the future.
FAU - Chen, Zhi
AU  - Chen Z
AD  - Department of Geriatrics, Tongji Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, 430030, China.
FAU - Ren, Xiang
AU  - Ren X
AD  - Department of Urology, Third Hospital of Shanxi Medical University, Shanxi 
      Bethune Hospital, Shanxi Academy of Medical Sciences, Taiyuan, 030032, China.
AD  - Tongji Shanxi Hospital, Tongji Medical College, Huazhong University of Science 
      and Technology, Taiyuan, 030032, China.
FAU - Ren, Ruimin
AU  - Ren R
AD  - Department of Urology, Third Hospital of Shanxi Medical University, Shanxi 
      Bethune Hospital, Shanxi Academy of Medical Sciences, Taiyuan, 030032, China.
AD  - Tongji Shanxi Hospital, Tongji Medical College, Huazhong University of Science 
      and Technology, Taiyuan, 030032, China.
FAU - Wang, Yonghong
AU  - Wang Y
AD  - Tongji Shanxi Hospital, Tongji Medical College, Huazhong University of Science 
      and Technology, Taiyuan, 030032, China.
AD  - Department of Neurosurgery, Third Hospital of Shanxi Medical University, Shanxi 
      Bethune Hospital, Shanxi Academy of Medical Sciences, Taiyuan, 030032, China.
FAU - Shang, Jiwen
AU  - Shang J
AD  - Tongji Shanxi Hospital, Tongji Medical College, Huazhong University of Science 
      and Technology, Taiyuan, 030032, China. sjw139@126.com.
AD  - Department of Ambulatory Surgery, Third Hospital of Shanxi Medical University, 
      Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, No. 99 Longcheng 
      Street, Taiyuan, 030032, Shanxi, China. sjw139@126.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210324
PL  - England
TA  - Stem Cell Res Ther
JT  - Stem cell research & therapy
JID - 101527581
RN  - 0 (Benzylamines)
RN  - 0 (Cyclams)
RN  - 0 (Heterocyclic Compounds)
RN  - 143011-72-7 (Granulocyte Colony-Stimulating Factor)
RN  - Q20Q21Q62J (Cisplatin)
RN  - S915P5499N (plerixafor)
SB  - IM
MH  - *Acute Kidney Injury/chemically induced/prevention & control
MH  - Animals
MH  - Benzylamines
MH  - Bone Marrow
MH  - Cisplatin/toxicity
MH  - Cyclams
MH  - Granulocyte Colony-Stimulating Factor
MH  - Hematopoietic Stem Cell Mobilization
MH  - *Heterocyclic Compounds/pharmacology
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Stem Cells
PMC - PMC7992860
OTO - NOTNLM
OT  - AMD3100
OT  - Acute kidney injury
OT  - Chemokine
OT  - Cisplatin nephrotoxicity
COIS- The authors declare that they have no competing interests.
EDAT- 2021/03/26 06:00
MHDA- 2021/07/09 06:00
PMCR- 2021/03/24
CRDT- 2021/03/25 05:40
PHST- 2021/01/21 00:00 [received]
PHST- 2021/03/04 00:00 [accepted]
PHST- 2021/03/25 05:40 [entrez]
PHST- 2021/03/26 06:00 [pubmed]
PHST- 2021/07/09 06:00 [medline]
PHST- 2021/03/24 00:00 [pmc-release]
AID - 10.1186/s13287-021-02268-y [pii]
AID - 2268 [pii]
AID - 10.1186/s13287-021-02268-y [doi]
PST - epublish
SO  - Stem Cell Res Ther. 2021 Mar 24;12(1):209. doi: 10.1186/s13287-021-02268-y.